Rob's Lobs

[Rob]

How dare ye stinkify my fine thread with sub-standard graphics?

. . . when does GooG report?

Oct. 19, after the close, one day prior to expiry. The estimate is $2.42, which, if it equals the actual earnings, will be an 83% year-over-year increase and make the trailing 12-month figure $7.92 and a mere 50.7 P/E for this powerhouse, based on yesterday's closing price.

Sorry for the handysnap; its just too easy.

Not unlike calculating the value of a company just by looking at a chart.

[Rob]

William O'Neil would say the right side of the cup is too low.

It's less than 3% lower. What's O'Neil's criterion?

[billyjoe]

Rob,
Draw a line from side to side. If it's not exactly even , that can be called a flawed base and will be if the breakout fails. I'm not making this up.

------------billyjoe

[Rob]

I don't think you're making anything up, BillyJoe, but my memory differs from yours regarding the right side of a cup. My recollection is that it is typically slightly lower, within a certain percentage (5%?) according to O'Neil.

[IIC]

I think 3% is OK...but there was an article in Monday's IBD that said the increase should be at least 20% up to the left side high...GOOG 's was not that much from 370.

But you could also say it is a double bottom that is failing.

Of course you could make up the rules as you go along...as taught by CANSLIM

[New-born baby]

How dare ye stinkify my fine thread with sub-standard graphics?

If you like, I can take a can of Karel's Disinfecting Deodorant and delete the post. That might cut the stench some

[Rob]

If you like, I can take a can of Karel's Disinfecting Deodorant and delete the post. That might cut the stench some

Thanks, NBB, no need for that. I was just pokin' fun at you.

[Rob]

Okay, I've got my copy of How to Make Money In Stocks, by William J. O'Neil, and here's a quote from para. 2 on p. 164:

When handles do occur, they should form in the upper half of the overall base structure, as measured from absolute peak to the low of the cup. This should be above the stock's 200-day moving average price. Handles forming in the lower half of the base or completely below the stock's 200-day line are weak, failure-prone price structures.

[New-born baby]

Okay, I've got my copy of How to Make Money In Stocks, by William J. O'Neil, and here's a quote from para. 2 on p. 164:

When handles do occur, they should form in the upper half of the overall base structure, as measured from absolute peak to the low of the cup. This should be above the stock's 200-day moving average price. Handles forming in the lower half of the base or completely below the stock's 200-day line are weak, failure-prone price structures.

Yes, that 200 day line is important, and of course, GOOG is above it now.

[billyjoe]

Rob,
I think he changed defininitions as each edition came out. Anyway, if the right side of the cup is lower , when it is filled it might only be half filled , thus resulting in half a breakout.

------------billyjoe

[Rob]

The all-time intraday high on the DOW is 11,750.28.

It just came 0.68 shy of hitting it a few minutes ago.

[Rob]

The all-time intraday high on the DOW is 11,750.28.

It just came 0.68 shy of hitting it a few minutes ago.

Just broke it. We are now in record high territory.

[New-born baby]

Just broke it. We are now in record high territory.

IF it can hold it, we are going to rocket!

[Rob]

Erbitux: Promising Results in First Line Treatment for Metastatic Colorectal Cancer

From http://tinyurl.com/oc8b8 (emphasis added):

Adding Cetuximab (Erbitux) to First-Line Chemotherapy Boosts Results in Metastatic Colorectal Cancer: Presented at ESMO
By Jill Stein

ISTANBUL, TURKEY -- October 3, 2006 -- Cetuximab (Erbitux) appears to improve tumor response and disease control in first-line treatment of metastatic colorectal cancer (mCRC) when added to 2 different chemotherapy regimens.

Volker Heinemann, MD, Director of Klinikhum Grosshadern, Medizinishe Klinik III, Munich, Germany, presented updated interim results of the ongoing trial during an oral session on October 2nd at the 31st European Society of Medical Oncology (ESMO) Congress.

The study randomized 84 patients with mCRC and a median Karnofsky Performance Status of more than 70%, cetuximab -- epidermal growth factor receptor (EGFR)-targeting antibody -- in combination with either XELIRI or XELOX.

The XELIRI regimen consisted of capecitabine 2 x 800 mg/m2 orally on days 1 to 14 plus irinotecan 200 mg/m2 intravenously on day 1. The XELOX regimen involved oral capecitabine 2 x 1000 mg/m2 on days 1 to 14 plus IV oxaliplatin 130 mg/m2 on day 1.

In both treatment arms, IV cetuximab was given at a dose of 400 mg/m2 on day 1 of the first 3-week cycle followed by 250 mg/m2 during each subsequent cycle.

The primary endpoint of objective response rate was 42% in the XELIRI arm and 65.5% in the XELOX arm. Disease control rates were 90.9% and 93.1%, respectively.

"Both treatments were highly effective and the disease control rates were high," Dr. Heinemann commented.

Without cetuximab, these regimens would be more likely to show disease control rates in the region of 40% and 50%, respectively, according to previous studies, he said.

"There was more hematological toxicity in the XELIRI arm but more neurotoxicity in the oxaliplatin arm, as would be expected," he added.

"These are promising results in the first-line setting," Dr. Heinemann concluded. The trial is continuing to recruit patients until November, 2006.

[Presentation title: Cetuximab Plus Capecitabine/Irinotecan (XELIRI) versus Cetuximab Plus Capecitabine/Oxaliplatin (XELOX) as First-Line Treatment for Patients With Metastatic Colorectal Cancer (CRC): A Randomized Trial of the AIO CRC Study Group. Abstract 327O]

[Rob]

My current EBAY long position is close to +16%, so I set a 5% trailing stop under it. I have mixed feelings about doing that, but, as the saying goes, "better safe than sorry."